190 related articles for article (PubMed ID: 19813275)
1. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.
Katzenstein HM; Chang KW; Krailo M; Chen Z; Finegold MJ; Rowland J; Reynolds M; Pappo A; London WB; Malogolowkin M;
Cancer; 2009 Dec; 115(24):5828-35. PubMed ID: 19813275
[TBL] [Abstract][Full Text] [Related]
2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
4. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
Malogolowkin MH; Katzenstein H; Krailo MD; Chen Z; Bowman L; Reynolds M; Finegold M; Greffe B; Rowland J; Newman K; Womer RB; London WB; Castleberry RP
J Clin Oncol; 2006 Jun; 24(18):2879-84. PubMed ID: 16782927
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
6. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
8. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
9. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
10. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
11. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
12. [Outcome of hepatoblastoma: experience with 63 patients received chemotherapy with the regimen C5V].
Liu G; Liu B; Li K; Dong K; Xiao X
Zhonghua Er Ke Za Zhi; 2015 Feb; 53(2):119-23. PubMed ID: 25876687
[TBL] [Abstract][Full Text] [Related]
13. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
15. Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Sullivan MJ
Cancer; 2009 Dec; 115(24):5623-6. PubMed ID: 19813276
[No Abstract] [Full Text] [Related]
16. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
O'Neill AF; Towbin AJ; Krailo MD; Xia C; Gao Y; McCarville MB; Meyers RL; McGahren ED; Tiao GM; Dunn SP; Langham MR; Weldon CB; Finegold MJ; Ranganathan S; Furman WL; Malogolowkin M; Rodriguez-Galindo C; Katzenstein HM
J Clin Oncol; 2017 Oct; 35(30):3465-3473. PubMed ID: 28892430
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
18. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
